Organization | Kyowa Hakko Kogyo

Kyowa Hakko Kogyo Report issue

For profit Phase 3 Phase 4

Founded: Tokyo Japan (1949)

Status: Acquired by Kyowa Hakko Kirin (2008)

Organization Overview

First Clinical Trial

2002

NCT00147316

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Kyowa Hakko | Kyowa Hakko Bio Co., Ltd. | Kyowa Hakko Kogyo Co. | Kyowa Hakko Kogyo Co., Ltd. | Kyowa Hakko Kogyo (Japan) providing the amino acids

Active Ingredients

Drugs in Phase 4 Trials (2)

benidipine (coniel) (1 trial)

hydrochlorothiazide (esidrix) (1 trial)

Drugs in Phase 3 Trials (1)

alteplase (Activase) (1 trial)

Drugs in Other Trials (8)

amino acids (Freamine) (1 trial)

cellulose (2 trials)

citicoline (3 trials)

citrulline (2 trials)

glutathione (Furadantin) (5 trials)

omega-3 fatty acids (Omacor) (1 trial)

sustamine (1 trial)

vitamin b13 (Orotic acid) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Brain Ischemia (Phase 3)

Cardiovascular Diseases (Phase 4)

Cerebral Infarction (Phase 3)

Infarction (Phase 3)

Ischemia (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 12
# of Trial APIs: 11